Company news

Biodesix, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

February 29, 2024

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

February 15, 2024

Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method

November 13, 2023

Biodesix Announces Third Quarter 2023 Results and Highlights

November 6, 2023

Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023

October 23, 2023

Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

September 6, 2023

Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

August 21, 2023

Biodesix Announces Second Quarter 2023 Results and Highlights

August 6, 2023

Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023

July 23, 2023

Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

July 11, 2023

Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

July 5, 2023

Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier

June 26, 2023

Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting

May 31, 2023

Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing

May 24, 2023

Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

May 17, 2023

Biodesix Announces First Quarter 2023 Results and Highlights

May 10, 2023

Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023

April 26, 2023

Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights

March 5, 2023

Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

February 20, 2023

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test

December 18, 2022

Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

December 15, 2022

Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

November 20, 2022

Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock

November 16, 2022

Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million

November 15, 2022

Biodesix Announces Proposed Public Offering of Common Stock

November 15, 2022

Biodesix Announces Third Quarter 2022 Results and Highlights

November 2, 2022

Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022

October 19, 2022

Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions

October 16, 2022

Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs

October 11, 2022

Biodesix Announces Preliminary Revenue for Third Quarter 2022

October 10, 2022

Biodesix Named a Top 100 Healthcare Technology Company of 2022

August 8, 2022

Biodesix Announces Second Quarter 2022 Results and Highlights

August 3, 2022

Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors

July 19, 2022

Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022

July 18, 2022

Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test

June 6, 2022

Biodesix Announces Research Agreement with Top US Cancer Center

June 2, 2022

Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference

May 11, 2022

Biodesix Announces First Quarter 2022 Results and Highlights

May 10, 2022

Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022

April 26, 2022

Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With Cancer

March 28, 2022

Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights

March 13, 2022

Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital

March 6, 2022

Biodesix Announces Impactful Clinical Data on the Primary Immune Response (PIR) Test at the IASLC 2022 Therapies of Lung Cancer Meeting

March 2, 2022

Biodesix to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022

February 27, 2022

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (Unaudited)

February 13, 2022

Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to Results

January 17, 2022

Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan

January 3, 2022

Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

December 7, 2021

Biodesix Partners with Spesana to Streamline Digital Access to Molecular Diagnostics for Precision Medicine in Lung Cancer

November 30, 2021

Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer

November 17, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks